SmithKline Paxil patents

FTC has opened an investigation "to determine whether SmithKline has engaged in unfair methods of competition...by preventing or impeding competition to Paxil from generic paroxetine," Apotex/Torpharm discloses in Dec. 5 court filing. The companies are in litigation over "late-listed" patents (1"The Pink Sheet" Dec. 4, p. 25)